"Revenues of $1.9 million for the fourth quarter of 2015, compared to $1.5 million for the same period in the prior year"
This seems like solid progress to me. Most of what I'm seeing is positive growth.
What is your source for an estimated revenue for anything higher than 2 million?
The general feel from analysts asking questions seemed more civil and less aggressive than questions asked to Nathan. I think Looby did a great job presenting himself and the company on the earnings call and don't think repercussion will be felt.
This year if anything, was larger than typical, because of the massive DARPA grant.
The only thing that doesn't look wonderful on the spread sheet to me is the gross profit being smaller than ideal. However, it's good Ekso is spending most of their money. This is what small cap stocks do. It's normally better to reinvest in growth than distribute profits as dividends at the small stage.
------
Revenues for the fourth quarter of 2015 increased $0.5 million, or 31%, to $1.9 million compared to the same period in the prior year.
Medical device revenue increased $0.2 million, or 22%, to $1.1 million for the three months ended December 31, 2015 when compared to the same period in the prior year. This increase was primarily due to an increase in recognized revenue associated with higher medical device sales in 2015.
Engineering services revenue increased by $0.3 million, or 46%, to $0.8 million for the three months ended December 31, 2015 when compared to the same period in the prior year. This increase was primarily due to an increase in net revenue generating projects.
Gross profit for the fourth quarter 2015 was ($0.2) million compared to $0.6 million for the fourth quarter of 2014.
Operating expenses were $6.5 million for the fourth quarter of 2015 compared to $5.4 million in the fourth quarter of 2014. Excluding the impact of non-cash stock based compensation of $0.5 million and $0.3 million in the fourth quarter of 2015 and 2014, respectively, operating expenses were up 18% due primarily to increased headcount and additional research and development costs associated with the industrial business.
